Grants per year
Personal profile
Research Interests
Dr. Hussain's research is focused on the development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer.
Dr. Hussain is a GU medical oncologist with a focus on prostate and bladder cancer.
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior to joining the Northwestern University faculty Dr. Hussain has served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology. At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain was a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force. She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE. Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net. She currently serves on the Clinical Practice Guidelines Committee and is an elected member of the ASCO Board of Directors. Dr. Hussain is the author of more than 240 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty publications. She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.
Training Experience
1983 | Internship, Wayne State University |
1986 | Residency, Wayne State University School of Medicine, Detroit, Michigan |
1989 | Fellowship, Wayne State University School of Medicine, Detroit, Michigan |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MBChB, Medicine and Surgery, Baghdad University College of Medicine, Baghdad, Iraq
… → 1980
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
CCSG Senior Leadership
Platanias, L. C. (PD/PI), Abdulkadir, S. A. (Other), Cella, D. (Other), Green, K. J. (Other) & Hussain, M. (Other)
8/1/23 → 7/31/25
Project: Research project
-
Therapeutic targeting of Aurora Kinase A in lethal prostate cancer using a novel inhibitor
Hussain, M. (PD/PI), Fenton, S. E. (Co-Investigator) & Yang, X. J. (Co-Investigator)
Emory University, U.S. Army Medical Research and Materiel Command
7/1/23 → 6/30/26
Project: Research project
-
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination with Abiraterone in Patients with Metastatic Prostate Cancer
Hussain, M. (PD/PI)
Pharmaceutical Research Associates, Inc., Arvinas Androgen Receptor, Inc.
6/1/23 → 6/1/26
Project: Research project
-
Prot #GLSI-21-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and
Hussain, M. (PD/PI)
5/31/23 → 5/31/26
Project: Research project
-
Tactical Approaches to Repress oncogenic Gene Expression in prostatic Tumors (TARGET)
Abdulkadir, S. A. (PD/PI), Abdulkadir, S. A. (PD/PI), Fenton, S. E. (Co-Investigator), Fenton, S. E. (Co-Investigator), Hussain, M. (Co-Investigator), Hussain, M. (Co-Investigator), Schiltz, G. E. (Co-Investigator) & Schiltz, G. E. (Co-Investigator)
University of Michigan, Prostate Cancer Foundation
2/10/23 → 2/9/26
Project: Research project
-
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, A. H., Agarwal, N., Beltran, H., Hussain, M. H., Sartor, O., Shore, N., Antonarakis, E. S., Armstrong, A. J., Calais, J., Carducci, M. A., Dorff, T. B., Efstathiou, J. A., Gleave, M., Gomella, L. G., Higano, C., Hope, T. A., Iagaru, A., Morgans, A. K., Morris, D. S. & Morris, M. J. & 14 others, , Jan 1 2025, In: cancer. 131, 1, e35612.Research output: Contribution to journal › Article › peer-review
Open Access -
Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024
VanderWeele, D. J. & Hussain, M., Jan 2025, In: European urology. 87, 1, p. 47-48 2 p.Research output: Contribution to journal › Editorial › peer-review
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Hussain, M., Kocherginsky, M., Agarwal, N., Adra, N., Zhang, J., Paller, C. J., Picus, J., Reichert, Z. R., Szmulewitz, R. Z., Tagawa, S. T., Kuzel, T. M., Bazzi, L. A., Daignault-Newton, S., Whang, Y. E., Dreicer, R., Stephenson, R. D., Rettig, M. B., Shevrin, D., Gerke, T. & Chinnaiyan, A. M. & 1 others, , Oct 1 2024, In: Clinical Cancer Research. 30, 19, p. 4318-4328 11 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations -
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
Lara, P. N., Mayerson, E., Gertz, E., Tangen, C., Goldkorn, A., van Loan, M., Hussain, M., Gupta, S., Zhang, J., Parikh, M., Twardowski, P., Quinn, D. I., LeBlanc, M., Vogelzang, N. J., Thompson, I. & Agarwal, N., Feb 2024, In: European urology. 85, 2, p. 171-176 6 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Bone Pain and Survival among Patients with Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial
Gebrael, G., Jo, Y., Swami, U., Plets, M., Hage Chehade, C., Narang, A., Gupta, S., Myint, Z. W., Sayegh, N., Tangen, C. M., Hussain, M., Dorff, T., Lara, P. N., Lerner, S. P., Thompson, I. & Agarwal, N., 2024, (Accepted/In press) In: JAMA network open. p. e2419966Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Datasets
-
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Unger, J. M. (Creator), Griffin, K. (Creator), Donaldson, G. W. (Creator), Baranowski, K. M. (Creator), Good, M. J. (Contributor), Reburiano, E. (Contributor), Hussain, M. (Creator), Monk, P. J. (Creator), Van Veldhuizen, P. J. (Contributor), Carducci, M. A. (Creator), Higano, C. S. (Contributor), Lara, P. N. (Creator), Tangen, C. M. (Creator), Quinn, D. I. (Creator), Wade, J. L. (Creator), Vogelzang, N. J. (Creator), Thompson, I. M. (Creator) & Moinpour, C. M. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4712609, https://springernature.figshare.com/collections/Patient-reported_outcomes_for_patients_with_metastatic_castration-resistant_prostate_cancer_receiving_docetaxel_and_Atrasentan_versus_docetaxel_and_placebo_in_a_randomized_phase_III_clinical_trial_SWOG_S0421_/4712609
Dataset